Latest & greatest articles for depression

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on depression or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on depression and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for depression

161. Inverted items and validity: A psychobiological evaluation of two measures of psychological resources and one depression scale Full Text available with Trip Pro

Inverted items and validity: A psychobiological evaluation of two measures of psychological resources and one depression scale Psychological resources and risk factors influence risk of coronary heart disease. We evaluated whether inverted items in the Self-esteem, Mastery, and Center for Epidemiological Studies Depression scales compromise validity in the context of coronary heart disease. In a population-based sample, validity was investigated by calculating correlations with other scales (n (...)  = 1004) and interleukin-6 (n = 374), and by analyzing the relationship with 8-year coronary heart disease risk (n = 1000). Negative items did not affect the validity of the resource scales. In contrast, positive items from Center for Epidemiological Studies Depression showed no significant relationships with biological variables. However, they had no major impact on the validity of the original scale.

2018 Health psychology open

162. Orbital and medial prefrontal cortex functional connectivity of major depression vulnerability and disease Full Text available with Trip Pro

Orbital and medial prefrontal cortex functional connectivity of major depression vulnerability and disease Pathophysiology models of major depression (MD) center on the dysfunction of various cortical areas within the orbital and medial prefrontal cortex. While independent structural and functional abnormalities in these areas are consistent findings in MD, the complex interactions among them and the rest of the cortex remain largely unexplored.We used resting-state functional magnetic

2018 Biological psychiatry. Cognitive neuroscience and neuroimaging

163. Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-on Treatment for Bipolar Depression: A Randomized Clinical Trial Full Text available with Trip Pro

Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-on Treatment for Bipolar Depression: A Randomized Clinical Trial More effective, tolerable interventions for bipolar depression treatment are needed. Transcranial direct current stimulation (tDCS) is a novel therapeutic modality with few severe adverse events that showed promising results for unipolar depression.To determine the efficacy and safety of tDCS as an add-on treatment for bipolar depression.A randomized, sham (...) -controlled, double-blind trial (the Bipolar Depression Electrical Treatment Trial [BETTER]) was conducted from July 1, 2014, to March 30, 2016, at an outpatient, single-center academic setting. Participants included 59 adults with type I or II bipolar disorder in a major depressive episode and receiving a stable pharmacologic regimen with 17-item Hamilton Depression Rating Scale (HDRS-17) scores higher than 17. Data were analyzed in the intention-to-treat sample.Ten daily 30-minute, 2-mA, anodal-left

2018 EvidenceUpdates

164. Longer initial assessment in primary care when depression is suspected

Longer initial assessment in primary care when depression is suspected Longer initial assessment in primary care when depression is suspected We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Longer initial assessment in primary care when depression is suspected Share: Reading time approx. 1 minute Symptoms of depression is a common cause (...) for patients consulting general practitioners in primary care. To be able to correctly diagnose depression at the initial assessment a thorough and thus time-consuming examination is needed. The assessment also needs to be documented with a test questionnaire. This is to understand the severity but also to initiate a relevant treatment and to plan the follow up. Question Are there any scientific studies that support that a longer initial assessment results in less pharmacological treatment and faster

2018 Swedish Council on Technology Assessement

165. Depression

Depression Scottish Palliative Care Guidelines - Depression Scottish Palliative Care Guidelines search / / / Depression Depression Introduction Depression: is strongly and consistently associated with a poor quality of life. causes more reduction in role and social functioning than would be due to the physical illness alone. reduces physical functioning. is often associated with symptoms that are difficult to control. has a major impact on the patient’s family. Treatment of depression can (...) significantly improve quality of life and is as effective in palliative care as in other situations. Assessment All patients should be assessed for depression. Physical symptoms commonly associated with depression can be caused by physical illness or treatments so may be less helpful in establishing a diagnosis. These can include: weight/appetite change insomnia loss of energy psychomotor slowing loss of libido Depressive symptoms in palliative care patients include: greater severity of dysphoric mood

2018 Scottish Palliative Care Guidelines

166. Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial Full Text available with Trip Pro

Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial Pharmacotherapy to rapidly relieve suicidal ideation in depression may reduce suicide risk. Rapid reduction in suicidal thoughts after ketamine treatment has mostly been studied in patients with low levels of suicidal ideation. The authors tested the acute effect of adjunctive subanesthetic intravenous ketamine on clinically significant suicidal ideation in patients with major (...) depressive disorder.In a randomized clinical trial, adults (N=80) with current major depressive disorder and a score ≥4 on the Scale for Suicidal Ideation (SSI), of whom 54% (N=43) were taking antidepressant medication, were randomly assigned to receive ketamine or midazolam infusion. The primary outcome measure was SSI score 24 hours after infusion (at day 1).The reduction in SSI score at day 1 was 4.96 points greater for the ketamine group compared with the midazolam group (95% CI=2.33, 7.59; Cohen's d

2018 EvidenceUpdates

167. Psychotherapy for major depressive disorder and generalized anxiety disorder: OHTAC recommendation

Psychotherapy for major depressive disorder and generalized anxiety disorder: OHTAC recommendation Psychotherapy for major depressive disorder and generalized anxiety disorder: OHTAC recommendation Psychotherapy for major depressive disorder and generalized anxiety disorder: OHTAC recommendation Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Health Quality Ontario. Psychotherapy for major depressive disorder and generalized anxiety disorder: OHTAC recommendation. Toronto: Health Quality Ontario (HQO). 2017 Authors' conclusions The Ontario Health Technology Advisory Committee recommends that evidence-based, structured, individual and group psychotherapy provided by nonphysicians be publicly funded for patients with major depressive disorder and/or generalized anxiety disorder Final publication URL Indexing Status

2018 Health Technology Assessment (HTA) Database.

168. Psychotherapy for major depressive disorder and generalized anxiety disorder: a health technology assessment

Psychotherapy for major depressive disorder and generalized anxiety disorder: a health technology assessment Psychotherapy for major depressive disorder and generalized anxiety disorder: a health technology assessment Psychotherapy for major depressive disorder and generalized anxiety disorder: a health technology assessment Health Quality Ontario Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Health Quality Ontario. Psychotherapy for major depressive disorder and generalized anxiety disorder: a health technology assessment. Toronto: Health Quality Ontario (HQO). Ontario health technology assessment series; 17(15). 2017 Authors' conclusions Compared with usual care, treatment with CBT, interpersonal therapy, or supportive therapy significantly reduces depression symptoms posttreatment. CBT significantly reduces anxiety symptoms

2018 Health Technology Assessment (HTA) Database.

169. MiR‐339 depresses cell proliferation via directly targeting S‐phase kinase‐associated protein 2 mRNA in lung cancer Full Text available with Trip Pro

MiR‐339 depresses cell proliferation via directly targeting S‐phase kinase‐associated protein 2 mRNA in lung cancer S-phase kinase-associated protein 2 (Skp2) takes great part in the development of multiple tumors. However, the post-transcriptional modulation mechanism of Skp2 remains unclear. Here, we present a new regulatory microRNA of Skp2, miR-339, which directly targets Skp2 to inhibit cell proliferation in lung cancer.The expression of miR-339 or Skp2 in lung cancer samples (...) proliferation in lung cancer. Overexpressed Skp2 accelerated miR-339-bated proliferation of lung cancer cells. MiR-339 inhibitor promoted cell proliferation in lung cancer, but Skp2 RNA interference reversed miR-339 inhibitor-driven cell proliferation.MiR-339 targets the 3'-untranslated region of Skp2 mRNA to depress the proliferation of lung cancer cells.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2018 Thoracic cancer

170. SSRIs for depression/heart failure patients? Not so fast

SSRIs for depression/heart failure patients? Not so fast SSRIs for depression/heart failure patients? Not so fast Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics SSRIs for depression/heart failure patients? Not so fast View/ Open Date 2017-09 Format Metadata Abstract This study should put to rest the practice (...) of starting SSRIs in depressed patients with heart failure in an attempt to affect CVD outcomes. PRACTICE CHANGER: Do not prescribe selective serotonin reuptake inhibitors to improve depression and reduce cardiovascular risk in patients with congestive heart failure. Stength of recommendation: B: Based on one large randomized controlled trial. URI Part of Citation Journal of Family Practice, 66(9) 2017: 564-567. Rights OpenAccess. This work is licensed under a Creative Commons Attribution-NonCommercial

2018 PURLS

171. Is the serum oxytocin level altered by treatment in rheumatoid arthritis patients complicated with depression? Full Text available with Trip Pro

Is the serum oxytocin level altered by treatment in rheumatoid arthritis patients complicated with depression? The objective of this study was to investigate the factors associated with depression, including serum oxytocin (OXT) levels, disease activity, activities of daily living (ADL), and quality of life (QOL), and their effects on rheumatoid arthritis (RA).This study included 42 RA patients who received treatment with a biological agent. We measured the following variables before and after (...) 6 months of treatment: baseline characteristics, including age, sex, disease duration, smoking, and body mass index (BMI); prednisolone and methotrexate dose; serum level of matrix metalloproteinase-3 (MMP-3); erythrocyte sedimentation rate (ESR); and C-reactive protein (CRP) level. The disease activity of RA was assessed using the Simplified Disease Activity Index (SDAI); depression was assessed using the Hamilton Depression Rating Scale (HAM-D); ADL was assessed using the Health Assessment

2018 European journal of rheumatology

172. A study on characteristics of rheumatoid arthritis patients achieving remission in depression with 6 months of bDMARDs treatment Full Text available with Trip Pro

A study on characteristics of rheumatoid arthritis patients achieving remission in depression with 6 months of bDMARDs treatment To investigate the relationship between baseline factors and depression remission after a 6-month biological disease-modifying antirheumatic drugs (bDMARDs) treatment in rheumatoid arthritis (RA) patients.The study was conducted in 152 RA patients treated with bDMARDs. The following patient's characteristics were studied: gender, age, disease duration, baseline (...) prednisolone dosage, and serum matrix metalloproteinase3 (MMP3) levels. For assessment, we used the simple disease activity index (SDAI) for RA disease activity, Health Assessment Questionnaire Disability Index (HAQ-DI) for activities of daily living (ADL), Short Form-36 for nonspecific health-related quality of life (QOL), and Hamilton Depression Rating Scale (HAM-D) scores for the depression status. Depressed remission was clarified using HAM-D ≤7 after 6 months of treatment. The patients were divided

2018 European journal of rheumatology

173. Contraceptives as possible risk factors for postpartum depression: A retrospective study of the food and drug administration adverse event reporting system, 2004–2015 Full Text available with Trip Pro

Contraceptives as possible risk factors for postpartum depression: A retrospective study of the food and drug administration adverse event reporting system, 2004–2015 Postpartum depression is a mood disorder that commonly affects women during the early postpartum period. The objective of this study was to analyse the association of postpartum depression with drugs (including contraceptive devices and implants) with spontaneously reported adverse events reported in the US Food and Drug (...) Administration Adverse Event Reporting System database.Retrospective study.Reports of postpartum depression events between 2004-2015 were analysed with a reporting odds ratio (ROR) algorithm. The Medical Dictionary for Regulatory Activities was used to identify postpartum depression.The reporting odds ratios (95% confidence intervals, CI) of levonorgestrel (an intrauterine device with progestogen), etonogestrel (a hormonal contraceptive implant), sertraline and drospirenone (an oral contraceptive) were 12.5

2018 Nursing open

174. Recent developments in the treatment of major depressive disorder in children and adolescents Full Text available with Trip Pro

Recent developments in the treatment of major depressive disorder in children and adolescents Recent developments in the treatment of major depressive disorder in children and adolescents | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Recent developments in the treatment of major depressive disorder in children and adolescents Article Text Clinical review Recent developments in the treatment of major depressive disorder in children

2018 Evidence-Based Mental Health

175. Mental health: Study supports augmentation with a non-antidepressant agent over combining or switching antidepressants in unipolar depression

Mental health: Study supports augmentation with a non-antidepressant agent over combining or switching antidepressants in unipolar depression Study supports augmentation with a non-antidepressant agent over combining or switching antidepressants in unipolar depression | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) depression Article Text Commentary Mental health Study supports augmentation with a non-antidepressant agent over combining or switching antidepressants in unipolar depression Stephan Köhler , Philipp Sterzer Statistics from Altmetric.com Commentary on : Mohamed S, Johnson GR, Chen P, et al. Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial. JAMA 2017;318,132–45

2018 Evidence-Based Medicine

176. Guidelines for the Evaluation and Treatment of Perimenopausal Depression

Guidelines for the Evaluation and Treatment of Perimenopausal Depression CE: ; MENO-D-18-00170; Total nos of Pages: 17; MENO-D-18-00170 CONSENSUS RECOMMENDATIONS Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations PaulineM.Maki,PhD, 1* SusanG.Kornstein,MD, 2* HadineJoffe,MD,MSc, 3 JoyceT.Bromberger,PhD, 4 Ellen W. Freeman, PhD, 5 Geena Athappilly, MD, 6 William V. Bobo, MD, MPH, 7 Leah H. Rubin, PhD, 8 Hristina K. Koleva, MD, 9 Lee S. Cohen, MD (...) , 10 Claudio N. Soares, MD, PhD, MBA, 11 on behalf of the Board of Trustees for The North American Menopause Society (NAMS) and the Women and Mood Disorders Task Force of the National Network of Depression Centers Abstract There is a new appreciation of the perimenopause – defined as the early and late menopause transition stages as well as the early postmenopause - as a window of vulnerability for the development of both depressive symptoms and major depressive episodes. However, clinical

2018 The North American Menopause Society

177. Study Protocol for a Randomized Double Blind, Placebo Controlled Trial Exploring the Effectiveness of a Micronutrient Formula in Improving Symptoms of Anxiety and Depression. Full Text available with Trip Pro

Study Protocol for a Randomized Double Blind, Placebo Controlled Trial Exploring the Effectiveness of a Micronutrient Formula in Improving Symptoms of Anxiety and Depression. Background: Anxiety and depression are conferring an increasing burden on society. Although treatments exist for both conditions, side effects, and difficulties accessing treatment prevent many people from receiving adequate assistance. Nutritional approaches have demonstrated some success in treating anxiety (...) and depression. We plan to investigate whether a micronutrient formula, Daily Essential Nutrients, improves symptoms of anxiety and depression compared to a placebo in a community recruited sample. Methods: This will be a randomized, double blind placebo controlled study (RCT). Two hundred adults will be assigned to either a placebo or micronutrient group (placebo or Daily Essential Nutrients (DEN)) in a 1:1 ratio. Baseline data will be collected for 2 weeks, followed by 10 weeks of placebo or micronutrient

2018 Medicines (Basel, Switzerland) Controlled trial quality: predicted high

178. Antidepressants for Adults with Depression using Opioid Medications: Clinical Effectiveness and Guidelines

Antidepressants for Adults with Depression using Opioid Medications: Clinical Effectiveness and Guidelines Antidepressants for Adults with Depression using Opioid Medications: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Antidepressants for Adults with Depression using Opioid Medications: Clinical Effectiveness and Guidelines Antidepressants for Adults with Depression using Opioid Medications: Clinical Effectiveness and Guidelines Last updated: February 16 (...) , 2018 Project Number: RB1196-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of antidepressants in adults with depression using opioid medications? What are the evidence-based guidelines informing the use of antidepressants in adults with depression using opioid medications? Key Message Two systematic reviews, one meta-analysis, four randomized controlled trials, and one evidence-based guideline was identified

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

179. Telehealth for the Assessment and Treatment of Depression, Post-Traumatic Stress Disorder, and Anxiety: Clinical Evidence

Telehealth for the Assessment and Treatment of Depression, Post-Traumatic Stress Disorder, and Anxiety: Clinical Evidence Telehealth for the Assessment and Treatment of Depression, Post-Traumatic Stress Disorder, and Anxiety: Clinical Evidence | CADTH.ca Find the information you need Telehealth for the Assessment and Treatment of Depression, Post-Traumatic Stress Disorder, and Anxiety: Clinical Evidence Telehealth for the Assessment and Treatment of Depression, Post-Traumatic Stress Disorder (...) , and Anxiety: Clinical Evidence Last updated: April 10, 2018 Project Number: RC0980-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of psychological assessment delivered via telehealth for patients with depression, post-traumatic stress disorder, or anxiety? What is the clinical effectiveness of psychological treatment delivered via telehealth for patients with depression, post-traumatic stress

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

180. e-Therapy Interventions for the Treatments of Patients with Depression: A Review of Clinical Effectiveness

e-Therapy Interventions for the Treatments of Patients with Depression: A Review of Clinical Effectiveness e-Therapy Interventions for the Treatments of Patients with Depression: A Review of Clinical Effectiveness | CADTH.ca Find the information you need e-Therapy Interventions for the Treatments of Patients with Depression: A Review of Clinical Effectiveness e-Therapy Interventions for the Treatments of Patients with Depression: A Review of Clinical Effectiveness Last updated: May 18, 2018 (...) Project Number: RC0983-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of e-therapy for the treatment of patients with depression? Key Message Evidence from a small number of systematic reviews (SRs) and small size randomized controlled trials (RCTs) consistently showed that therapist-guided e-therapy was superior to no treatment, wait list, or TAU in reducing depressive symptoms

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review